Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebocontrolled, double-blind study - Wemeau, J L; Caron, P; Beckers, A; Rohmer, V; Orgiazzi, J; Borson-Chazot, F; Nocuadie, M; Perimenis, P; Bisot-Locard, S; Bourdeix, I; Dejager, S (J Clin Endocrinol Metab, 2005)